众生药业发布异动公告称，目前，公司正在推进昂拉地韦颗粒治疗2~11岁儿童单纯性甲型流感患者和 昂拉地韦片治疗12~17岁青少年单纯性甲型流感患者的两项III期临床试验、RAY1225注射液治疗肥胖/超 重患者的III期临床试验、以及RAY1225注射液治疗2型糖尿病患者的两项III期临床试验。创新药研发项 目的临床试验进度、审评和审批的结果以及未来产品市场竞争格局都具有一定的不确定性。药品能否获 批上市以及获批上市的时间、上市后的生产和销售情况存在不确定性。此外，用于治疗成人单纯性甲型 流感的小分子创新药昂拉地韦片已获得国家药品监督管理局批准上市，是全球首款流感RNA聚合酶PB2 蛋白抑制剂。未来昂拉地韦片的商业化和销售情况存在不确定性。（第一财经） ...

每经AI快讯，11月16日，众生药业（002317）(002317.SZ)发布股票交易异常波动的公告，目前，公司 正在推进昂拉地韦颗粒治疗2~11岁儿童单纯性甲型流感患者和昂拉地韦片治疗12~17岁青少年单纯性甲 型流感患者的两项III期临床试验、RAY1225注射液治疗肥胖/超重患者的III期临床试验、以及RAY1225 注射液治疗2型糖尿病患者的两项III期临床试验。创新药研发项目的临床试验进度、审评和审批的结果 以及未来产品市场竞争格局都具有一定的不确定性。药品能否获批上市以及获批上市的时间、上市后的 生产和销售情况存在不确定性。此外，用于治疗成人单纯性甲型流感的小分子创新药昂拉地韦片已获得 国家药品监督管理局批准上市，是全球首款流感RNA聚合酶PB2蛋白抑制剂。未来昂拉地韦片的商业化 和销售情况存在不确定性。 ...

南财智讯11月16日电，众生药业公告，公司股票于2025年11月12日、11月13日及11月14日连续三个交易 日内日收盘价格涨幅偏离值累计超过20%，根据相关规定，属于股票交易异常波动的情况。经公司董事 会核查，公司未发现前期披露的信息存在需要更正或补充之处；近期无公共传媒报道可能对公司股价产 生较大影响的未公开重大信息；目前经营情况正常，内外部经营环境未发生重大变化；公司、控股股东 及实际控制人不存在应披露而未披露的重大事项，也未在筹划相关重大事项；控股股东及实际控制人在 股票异常波动期间未买卖公司股票。公司董事会确认，目前没有任何应予披露而未披露的事项，亦未获 悉任何可能对公司股票交易价格产生较大影响的信息。此外，公司提示，多项创新药临床试验正在推进 中，研发进度、审批结果及未来市场竞争存在不确定性；已获批上市的昂拉地韦片商业化进程也可能受 到市场、政策及竞争产品等多重因素影响，未来销售情况存在不确定性。公司不存在违反信息公平披露 的情形。 ...

Core Viewpoint - The company is advancing multiple Phase III clinical trials for its innovative drugs, including treatments for influenza and obesity, but faces uncertainties regarding approval and market competition [1] Group 1: Clinical Trials - The company is conducting Phase III clinical trials for the following: - Anglatide granules for treating uncomplicated influenza in children aged 2-11 - Anglatide tablets for treating uncomplicated influenza in adolescents aged 12-17 - RAY1225 injection for treating obesity/overweight patients - RAY1225 injection for treating Type 2 diabetes patients [1] Group 2: Drug Approval and Market Uncertainty - The small molecule innovative drug Anglatide tablets, approved by the National Medical Products Administration, is the world's first influenza RNA polymerase PB2 protein inhibitor - The commercialization of drugs post-approval is subject to uncertainties influenced by market conditions, policy changes, and environmental factors - The future sales and commercialization of Anglatide tablets may be affected by the prevalence of preventive vaccines, the approval of other therapeutic drugs, and subsequent product marketing efforts [1]

智通财经APP讯，众生药业(002317.SZ)公告称，目前，公司正在推进昂拉地韦颗粒治疗2~11岁儿童单纯 性甲型流感患者和昂拉地韦片治疗12~17岁青少年单纯性甲型流感患者的两项III期临床试验、RAY1225 注射液治疗肥胖/超重患者的III期临床试验、以及RAY1225注射液治疗2型糖尿病患者的两项III期临床试 验。创新药研发项目的临床试验进度、审评和审批的结果以及未来产品市场竞争格局都具有一定的不确 定性。药品能否获批上市以及获批上市的时间、上市后的生产和销售情况存在不确定性。 用于治疗成人单纯性甲型流感的小分子创新药昂拉地韦片已获得国家药品监督管理局批准上市，是全球 首款流感RNA聚合酶PB2蛋白抑制剂。由于医药产品的行业特点，药品获批后的商业化将受到市场、政 策、环境变化等不确定因素影响，并且受相关疾病的预防性疫苗的普及、治疗药物的陆续获批、后续产 品市场推广等多种因素影响，未来昂拉地韦片的商业化和销售情况存在不确定性。 ...

证券代码：002317 公告编号：2025-108 广东众生药业股份有限公司 关于公司股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 广东众生药业股份有限公司（以下简称"公司"）股票（证券简称：众生药 业，证券代码：002317）于 2025 年 11 月 12 日、11 月 13 日及 11 月 14 日连续 三个交易日内日收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易 规则》等有关规定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 针对公司股票异常波动，公司董事会对公司、公司控股股东及实际控制人就 有关事项进行了核查，现就有关情况说明如下： 1、公司未发现前期披露的信息存在需要更正、补充之处； 3、公司目前经营情况正常，内外部经营环境未发生重大变化； 4、公司、控股股东及实际控制人不存在关于公司的应披露而未披露的重大 事项，也不存在处于筹划阶段的重大事项； 5、公司控股股东及实际控制人在本公司股票交易异常波动期间未买卖本公 司股票。 三、是否存在应披露而未披露信息的说明 公司 ...

Core Viewpoint - The health industry is experiencing significant growth, with multiple stocks showing strong performance and attracting substantial investment [1][9][14]. Market Overview - The A-share market has been fluctuating at high levels, with the Shanghai Composite Index reaching a 10-year high before retreating, and major indices like the Shenzhen Component and ChiNext showing slight declines [2]. - The total trading volume for the week was approximately 10.22 trillion yuan, with daily trading around 2 trillion yuan [2]. Financing Trends - Year-to-date, net financing purchases have reached 634 billion yuan, with over 12.6 billion yuan net bought in the last week alone [3][4]. - The power equipment sector saw over 5.3 billion yuan in net purchases, while the non-ferrous metals and basic chemicals sectors also attracted significant investment [4]. Banking Sector Performance - The banking sector has been performing exceptionally well, with indices frequently hitting historical highs. Over the past three years, bank stocks have risen by 94%, significantly outperforming the Shanghai Composite Index [6]. - Agricultural Bank of China has shown remarkable growth, with a cumulative increase of 317% over four years [6]. Health Industry Insights - The health industry has seen a surge in stock performance, particularly in pharmaceutical and biopharmaceutical sectors, with several stocks experiencing consecutive daily gains [10][14]. - The Chinese government has implemented various policies to support the health industry, anticipating a market size of 17.4 trillion yuan by 2025 and 29.1 trillion yuan by 2030 [13][14]. Future Market Outlook - Analysts suggest that the market will stabilize, with structural trends becoming more prominent. Investment opportunities are expected in sectors like TMT, coal, and banking [15]. - The technology sector is anticipated to show mixed performance, with only those stocks backed by solid earnings likely to see upward movement [15].

Core Insights - The main point of the articles is the analysis of capital flow in various industries and individual stocks, highlighting significant net inflows and outflows in the market on November 14. Industry Summary - The total net outflow of main capital in the Shanghai and Shenzhen markets reached 620.11 billion yuan, with the ChiNext board experiencing a net outflow of 257.8 billion yuan and the CSI 300 index seeing a net outflow of 204.39 billion yuan [1]. - Among the 25 declining industries, the electronics sector had the largest drop at 3.09%, while the telecommunications and media sectors also fell by over 2% [1]. - Five industries saw net inflows, with the defense and military industry leading at 8.46 million yuan, followed by the real estate sector with 5.45 million yuan, and both the construction decoration and pharmaceutical industries exceeding 4 million yuan in net inflows [1]. Stock Summary - A total of 21 stocks experienced net inflows exceeding 2 billion yuan, with 10 stocks seeing inflows over 3 billion yuan. Leading the inflows was XianDao Intelligent with 9.4 billion yuan, attributed to high-margin orders from major domestic and international clients [3]. - Aerospace Development followed with a net inflow of 7.52 billion yuan, reporting a 16.8% year-on-year increase in revenue for the first three quarters [3]. - Other notable stocks with significant net inflows included Yingxin Development (6.34 billion yuan), Zhongsheng Pharmaceutical (6.19 billion yuan), CIMC (6 billion yuan), and Hainan Development (4.84 billion yuan) [4]. - Conversely, 23 stocks had net outflows exceeding 5 billion yuan, with the leading outflow from Xinyi Sheng at 15.92 billion yuan, particularly affecting sectors like computing, PCB, and storage chips [5].

Market Overview - On November 14, A-shares saw a collective decline in the three major indices, with the Shanghai Composite Index dropping by 0.97% to 3990 points and the Shenzhen Component Index falling by 1.93%. The total market turnover was 1.98 trillion yuan, a decrease of 853 billion yuan from the previous trading day, with over 3300 stocks declining. The storage chip, HBM concept, and semiconductor sectors experienced the largest declines, while the Hainan sector, gas stocks, and aquaculture sectors saw gains [1]. Stock Performance - Notable gainers included *ST Yumo (+5.06%), ST Huapeng (+4.92%), and *ST Ping (+4.94%). *ST Lvkang surged by 45.00%, while Furi Co. rose by 9.99%. Dongzi Group and Sanmu Group both increased by approximately 10% [2][3]. - The top three stocks by net buying on the daily leaderboard were Aerospace Development (+10.06%), Space Technology (+6.70%), and Kangzhi Pharmaceutical (+20.00%), with net buying amounts of 2.79 billion yuan, 1.69 billion yuan, and 1.42 billion yuan, respectively [5]. Institutional Activity - The top three stocks with net selling by institutions were Zhaoyi Innovation (-9.55%), Fuxiang Pharmaceutical (-2.66%), and Huasheng Lithium Electric (-2.49%), with net selling amounts of 10.95 billion yuan, 2.66 billion yuan, and 2.49 billion yuan, respectively [6][8]. - Among stocks involving institutional special seats, the top three for net buying were Space Technology (2.08 billion yuan), Hailu Heavy Industry (1.41 billion yuan), and Zhongyi Technology (1.13 billion yuan) [7]. Sector Highlights - Aerospace Development, involved in military-civilian integration and the Fujian Free Trade Zone, saw a significant increase, with a turnover of 25.29 billion yuan and a trading rate of 17.05%. The stock is linked to satellite internet and military information technology, which are currently active sectors [9][13]. - Lianhua Technology, associated with CRO concepts and fluorochemical concepts, also experienced a surge, with a turnover of 22.04 billion yuan and a trading rate of 16.49%. Institutional net buying reached 1.02 billion yuan [14][18]. - The company Daybreak Oriental, which is involved in bank equity and energy-saving construction, saw a trading rate of 7.69% and a turnover of 6.68 billion yuan, with net buying from the Shanghai Stock Connect [19][23]. Financial Performance - Unified Co. reported a total revenue of 19.16 billion yuan, a year-on-year increase of 4.77%, and a net profit of 4920.34 million yuan, reflecting a significant year-on-year growth of 84.70% [27].

Market Performance - As of November 14, the pharmaceutical e-commerce sector rose by 1.24%, ranking 9th among concept sectors, with 93 stocks increasing in value [1] - Notable gainers included Shuyuan Pharmaceutical and Kangzhi Pharmaceutical, both reaching a 20% limit up, while Jiaying Pharmaceutical and People's Tongtai also hit the limit up [1] - The top gainers in the sector included Jinshiyao, Minsheng Health, and Jiashitang, which rose by 8.10%, 7.62%, and 5.97% respectively [1] Capital Inflow - The pharmaceutical e-commerce sector saw a net inflow of 1.058 billion yuan, with 70 stocks receiving net inflows, and 5 stocks exceeding 100 million yuan in net inflow [2] - The leading stock in terms of net inflow was Zhongsheng Pharmaceutical, with a net inflow of 732 million yuan, followed by Te Yi Pharmaceutical and Kangzhi Pharmaceutical with net inflows of 299 million yuan and 258 million yuan respectively [2] Stock Performance - The stocks with the highest net inflow ratios included ST Zhongzhu, Shuyuan Pharmaceutical, and Zhongsheng Pharmaceutical, with net inflow ratios of 42.18%, 37.31%, and 36.05% respectively [3] - Notable stock performances included Zhongsheng Pharmaceutical and Te Yi Pharmaceutical both achieving a 9.98% increase, while Kangzhi Pharmaceutical reached a 20% increase [3][4] Additional Insights - The pharmaceutical e-commerce sector's performance was supported by significant capital inflows, indicating strong investor interest [2][3] - The overall market sentiment appears positive for the pharmaceutical e-commerce sector, as evidenced by the number of stocks hitting the upper limit and the substantial net inflows [1][2]